Business, energy, technology, markets and global industry news from Business News Today

Aficamten

PharmaDeviceNews Aficamten
Representative image: A cardiologist reviews heart imaging as Cytokinetics’ $CYTK aficamten gains UK approval and NICE backing for approximately 6,600 adults with symptomatic obstructive hypertrophic cardiomyopathy.
Pharma & Biotech

Aficamten wins UK approval and NICE backing for 6,600 adults with obstructive HCM

Aficamten gains UK authorisation and NICE backing for symptomatic obstructive HCM after Phase 3 improvements in exercise capacity.

Read More
Pharma & Biotech

Edgewise Therapeutics’ Phase 2 HCM data put systolic function into sharper focus

Find out how Edgewise Therapeutics’ EDG-7500 data could reshape HCM drug development as Phase 3 questions emerge.

Read More